Michelle S Miller
Michelle completed her PhD in Medicinal Chemistry in the laboratory of Dr. Philip Thompson at the Monash Institute of Pharmaceutical Sciences, working on developing isoform selective inhibitors for PI3K. She then moved to Johns Hopkins University in the USA to do a postdoc in the labs of Dr. Sandra Gabelli and Dr. Bert Vogelstein. While in the US, she worked on a number of different projects including determining the first lipid-substrate bound structure of PI3Kalpha and the discovery of an allosteric binding site for PI3K oncogenic mutant selective inhibitor design. Her more recent work has focused on mutant neoantigens as targets for immunotherapy and using protein structure to inform the design and development of novel immunotherapy tools. She has recently moved back to Melbourne and is currently working at WEHI with Drs. Peter Colman and Peter Czabotar.
Abstracts this author is presenting:
